This is a working overview of reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
In 2010, the International Nomenclature Group for Constitutional Disorders of the Skeleton (INCDS) "freed" the Sillence types from molecular reference, acquiescing to their new clinical-first role in the wake of what was to them a "surprising" increase in the number of genetic causes of OI. Writing for the Annual Review of Genetics in 2012, Drs. Peter Byers and Shawna M. Pyott lamented how the expansion of the number of types to include genetic types has created a system that "grew like Topsy". They suggest that it may indeed be impossible to create a system which is useful for clinicians and which accurately describes the genetic cause of a person's OI, with attempts always prioritizing one use at the expense of the other.
Fibrillar sliding, or the process of shear as load is applied, enabling plasticity Fibril bridging across the region of a crack Crack deflection at the tip of crack, where stress concentration can lead to further propagation and eventual failure. These mechanisms work together to resist fracture, allowing these materials to withstand millions of cycles of load without failure, essential for mobile living beings. Another mechanical advantage of biopolymers is their ability to be strained, resulting from the existence of strong fibrillar structures in a more compliant matrix material. The good deformability of interfacial matrices plays a key role in allowing for reorientation of constituents during deformation.
== Research == G protein-biased MOR agonists like SR-17018 have potential medical applications as analgesics in the treatment of pain and as opioid substitutes in the treatment of opioid dependence and withdrawal. However, it remains unclear whether G protein-biased MOR agonists, such as SR-17018 and oliceridine, are truly clinically advantageous to conventional MOR agonists. SR-17018 has only been assessed in preclinical research and has not been formally studied in humans. Improved analogues of SR-17018 are being studied by Laura Bohn and colleagues as of December 2025.
Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy of the retina, glomerulopathy C3 and membranoproliferative globulonephritis. Pegcetacoplan is a complement inhibitor. The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue. Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells). Pegcetacoplan is the first treatment for paroxysmal nocturnal hemoglobinuria that binds to and inhibits complement protein C3. Pegcetacoplan was approved for medical use in the United States in May 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. In 2024, the American Society of Nephrology Annual Kidney Meeting, the study group who investigating pegcetacoplan in the largest multicenter double-blind VALIANT trial, showed its significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated membranoproliferative glomerulonephritis. C3 glomerulopathy leads to kidney failure in approximately 50% of patients within 5–10 years of diagnosis, and even when patients do receive a kidney transplant, approximately two thirds experience disease recurrence.
Sources: en.wikipedia.org
Breastfeeding Resources – La Leche League International (archived 6 November 2006) "Breast-Feeding Content Resources" – WHO reports on Breast Feeding "Breastfeeding and Breast Milk" – US National Institute of Health Center for Disease Control and Prevention Breastfeeding Academy of Breastfeeding Medicine The World Alliance for Breastfeeding Action LactMed – a database of the safety of drugs to which breastfeeding mothers may be exposed by the US National Library of Medicine
What is behavior? Baby don't ask me, don't ask me, no more at Earthling Nature. behaviorinformatics.org Links to review articles by Eric Turkheimer and co-authors on behavior research Links to IJCAI2013 tutorial on behavior informatics and computing
In Kwannon's first appearance, using the codename Revanche, she traveled to the United States to confront Braddock, believing herself to be the real Betsy Braddock due to amnesia caused by the body swap. She discovered that she was formerly the Hand's prime assassin before incurring brain damage and falling comatose as a result of a battle with her lover Matsu'o Tsurayaba, a high-ranking member of the Hand. In hopes that, due to Kwannon's low-level psychic abilities, the powers of the high-level telepath Betsy Braddock would be able to save her life, Tsurayaba sought the help of the sorceress Spiral, who instead transferred the women's minds into each other's bodies rather than simply recovering Kwannon. After accepting that she is not the original Betsy Braddock, Kwannon becomes a member of the X-Men, shortly thereafter contracting the Legacy Virus. As the disease progressed, Kwannon's psychic abilities increased, allowing her to clarify her own distorted memory. Choosing to die on her own terms, Kwannon confronts Tsurayaba, who complies with her request to kill her rather than waiting to succumb to the disease. Following the Hunt for Wolverine, when Braddock was restored to her original body, Kwannon was reborn in her original body as well. Claiming the codename Psylocke for herself, Kwannon became a citizen of the mutant nation of Krakoa. After the apparent murder of her long-lost daughter by a threatening artificial intelligence called Apoth, Psylocke assembled a new team of Fallen Angels with X-23 and Cable.
== Substrate specificity == APX enzymes show high specificity for ascorbate as an electron donor, but most APXs will also oxidise other organic substrates that are more characteristic of the class III peroxidases (such as horseradish peroxidase), in some cases at rates comparable to that of ascorbate itself. This means that defining an enzyme as an APX is not straightforward, but is usually applied when the specific activity for ascorbate is higher than that for other substrates. Some proteins from the APX family lack the ascorbate-binding amino acid residues suggesting that they might oxidize other molecules than ascorbate.
== Role in non-mammalian vertebrates == In mammals, studies suggest that CRH has no significant thyrotropic effect. However, in representatives of all non-mammalian vertebrates, it has been found that, in addition to its corticotropic function, CRH has a potent thyrotropic function, acting with TRH to control the hypothalamic–pituitary–thyroid axis (TRH has been found to be less potent than CRH in some species).
Sources: en.wikipedia.org
== Historical background == The Darcy-Weisbach equation, combined with the Moody chart for calculating head losses in pipes, is traditionally attributed to Henry Darcy, Julius Weisbach, and Lewis Ferry Moody. However, the development of these formulas and charts also involved other scientists and engineers over its historical development. Generally, the Bernoulli's equation would provide the head losses but in terms of quantities not known a priori, such as pressure. Therefore, empirical relationships were sought to correlate the head loss with quantities like pipe diameter and fluid velocity. Julius Weisbach was certainly not the first to introduce a formula correlating the length and diameter of a pipe to the square of the fluid velocity. Antoine Chézy (1718-1798), in fact, had published a formula in 1770 that, although referring to open channels (i.e., not under pressure), was formally identical to the one Weisbach would later introduce, provided it was reformulated in terms of the hydraulic radius. However, Chézy's formula was lost until 1800, when Gaspard de Prony (a former student of his) published an account describing his results. It is likely that Weisbach was aware of Chézy's formula through Prony's publications. Weisbach's formula was proposed in 1845 in the form we still use today:
=== Antimicrobial scrubs === Antimicrobial scrubs can reduce the accumulation of odors and stains on scrubs, which in turn improves their longevity. These scrubs also come in a variety of colors and styles. As antimicrobial technology develops at a rapid pace, these scrubs are readily available, with more advanced versions hitting the market every year. These bacteria could then be spread to office desks, break rooms, computers, and other shared technology. This can lead to outbreaks and infections like methicillin-resistant staphylococcus aureus, treatments for which cost the healthcare industry $20 billion a year.
The political situation in Iran was a flashpoint between the major players in 1945–1946, with the Soviet Union sponsoring two breakaway provinces in northern Iran, adjacent to the Azerbaijan Soviet Socialist Republic. Soviet troops were stationed in northwestern Iran as part of the Anglo-Soviet invasion of Iran during the war. They not only refused to withdraw in 1945 but backed revolts that established short-lived, pro-Soviet separatist national states called the Azerbaijan People's Government and the Republic of Kurdistan. The issue was debated at the United Nations, and in 1946 Moscow abandoned its position, and the conflict was permanently resolved peacefully, with a pro-western government resuming control. Iran did not become a major battlefield of the Cold War, but it had its own history of confrontation with Britain and the United States. The long-standing conflict between Arabs and Jews in Mandatory Palestine continued after 1945, with Britain and in an increasingly impossible situation as the mandate holder. The Balfour Declaration of 1917 calling for a homeland for the Jews was supported in 1947 by both the Soviet Union and the United States. Both countries promptly Recognize the independent state of Israel in 1948. The Soviet Union later broke with Israel to support its Arab enemies. The region was more of an independent trouble zone rather than a playing field of the Cold War, and was not a precipitating factor in the Cold War. By 1953, Arab nationalism based in Egypt was a neutralizing force. The Soviet Union leaned increasingly toward Egypt.
=== Drug target === POMC is a pharmacological target for obesity treatment. The combination drug naltrexone/bupropion acts on hypothalamic POMC neurons to reduce appetite and food intake. In rare cases of POMC deficiency, treatment with setmelanotide, a selective melanocortin-4 receptor agonist, has been effective. Two individuals with confirmed POMC deficiency showed clinical improvement following this therapy.
Due to the mutiny of the Military Police of Espírito Santo State in which the agents demanded the correction of the remuneration for inflation, along with retroactive payments, criminal gangs and drug traffickers took advantage of the situation and a crime wave of violence, carjacking and looting spread across Espírito Santo, with most public services and businesses being closed. The Espírito Santo state government called in assistance from the National Public Security Force and the Brazilian Armed Forces to restore law and order in Vitória and other cities until military policemen began to return to their duties after two weeks of strike action. By 25 February, all military policemen in Espírito Santo had ended their strikes. At least 215 people were killed in the violence.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.